Scripps Genomics Health Initiative

Sponsor
Scripps Translational Science Institute (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT00808587
Collaborator
Navigenics, Inc. (Industry), Affymetrix, Inc. (Industry)
10,000
1
245
40.8

Study Details

Study Description

Brief Summary

The specific aims for this project are to enroll up to 10,000 subjects who will have their genomes surveyed using the Navigenics™ Health Compass technology. The Navigenics Health Compass helps you understand what your genetic variants have to say about the future of your health, and gives you action steps to take control of your health today. In addition, the investigators will assess how the Navigenics Health Compass, results affect lifestyle decisions. The phenotyping information that can be analyzed with the resulting Navigenics genotype information will assist in identifying genetic variations associated with other traits and diseases.

The uses of molecular markers such as cholesterol and glucose levels to assess disease risk are well established in clinical medicine today. Although these tools are useful in screening for subclinical disease, their predictive value is limited. Until recently, these molecular markers were the best risk assessment and screening tools in existence. Since the completion of the Human Genome Project, the era of personalized medicine, which exploits knowledge of the genes an individual carries that may predispose him/her to disease, has come to the forefront of research.

The Navigenics Health Compass technology assesses risk for about over 20 common diseases and provides subjects with more accurate assessments of their individual predictive risk for developing these conditions than traditional biomarkers such as cholesterol and glucose levels. This may positively influence changes in lifestyle, as well as decisions to seek further medical evaluation associated with preventive strategies.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    10000 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Scripps Genomics Health Initiative
    Study Start Date :
    Oct 1, 2008
    Actual Primary Completion Date :
    Sep 1, 2009
    Anticipated Study Completion Date :
    Mar 1, 2029

    Arms and Interventions

    Arm Intervention/Treatment
    No Treatment

    Outcome Measures

    Primary Outcome Measures

    1. The primary endpoint will be lifestyle changes based on the subject's genetic risk(s). [Three and 12 months]

    Secondary Outcome Measures

    1. The secondary endpoint will be to evaluate the frequency of subjects changing their lifestyle based on factors such as education, gender, disease history, and related items. [Three and 12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age 18 or older

    • Able to read, write, and fluently understand English.

    • Be reliable, cooperative, and willing to comply with all protocol specified procedures.

    • Be able to understand and grant informed consent.

    • Be able to provide payment for services rendered.

    • Have an email address.

    Exclusion Criteria:
    • Intake of anything orally, i.e., food, beverage, cigarettes, brushing of teeth, 30 minutes prior to providing saliva sample.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Scripps Health San Diego California United States 92037

    Sponsors and Collaborators

    • Scripps Translational Science Institute
    • Navigenics, Inc.
    • Affymetrix, Inc.

    Investigators

    • Principal Investigator: Eric J. Topol, MD, Scripps Translational Science Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Eric Topol, MD, Director, Scripps Translational Science Institute
    ClinicalTrials.gov Identifier:
    NCT00808587
    Other Study ID Numbers:
    • HSC# 08-5069
    First Posted:
    Dec 16, 2008
    Last Update Posted:
    Mar 17, 2021
    Last Verified:
    Mar 1, 2021
    Keywords provided by Eric Topol, MD, Director, Scripps Translational Science Institute

    Study Results

    No Results Posted as of Mar 17, 2021